medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2011, Number 6

<< Back Next >>

Rev Mex Urol 2011; 71 (6)

Evaluación metabólica ambulatoria de 27 pacientes con urolitiasis de alto riesgo de recurrencia en el Centro Médico del ISSEMyM

López-Zepeda A, Gutiérrez-Rosales R, Aragón-Castro Marco A, Guadarrama-Benítez B, Costilla-Montero A, Pérez-Guadarrama AO, Cisneros-Chávez R

Language: Spanish
References: 22
Page: 314-318
PDF size: 438.70 Kb.


ABSTRACT

Introduction: Outpatient metabolic evaluation is a useful diagnostic focus in the approach to urolithiasis, a disease that should be considered to be a metabolic pathology with tendency to recur.
Objective: To diagnose metabolic alterations and determine their prevalence in high recurrence risk patients along with their impact in relation to sex and age.
Methods: Descriptive study of twenty-seven patients (sixteen men and eleven women) presenting with high recurrence risk lithiasis was carried out. Calciuria, uricosuria, phosphaturia, oxaluria, citraturia, and creatinuria were quantified in 24-hour samples. Serum levels of calcium, uric acid, phosphorous, and parathyroid hormone were also determined. Student’s t test was used in the statistical analysis and statistical significance was a P ≤ 0.05.
Results: At least one metabolic alteration was diagnosed in 74.04% (20/27) of patients and 40.7% (11/27) presented with two or more metabolic alterations. The most frequent were hypercalciuria 29.62% (8/27), hypocitraturia 29.62% (8/27), hyperoxaluria 25.9% (7/27), and hyperuricemia 22.2% (6/27). No significant differences between groups in relation to age or sex were observed.
Discussion: Reported worldwide figures for metabolic diagnoses in these patients vary from 70-95%, results that are similar to those found in the present study.
Conclusions: A total of 74.04% patients were diagnosed with some type of metabolic change, demonstrating the need for carrying out metabolic studies in high risk patients, since specific medical management of these alterations for reducing lithiasis recurrence already exists.


REFERENCES

  1. Stamatelou KK, Francis ME, Jones CA, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63:1817-23.

  2. Curhan GC. Epidemiology of stone disease. Urol Clin North Am 2007;34:287-93.

  3. Hans-Goran Tiselius. Stone incidence and prevention. Braz J Urol 2000;26:452-62.

  4. Johnson CM, Wilson DM, O’Fallon WM, et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979;16:624-31.

  5. Ljunghall S, Danielson BG. A prospective study of renal stone recurrences. Br J Urol 1984;56:122-4.

  6. Pak CY, Resnick MI, Preminger GM. Ethnic and geographic diversity of stone disease. Urology 1997;50:504-7.

  7. Pak CY, Skurla C, Harvey J. Graphic display of urinary risk factors for renal stone formation. J Urol 1985;134:867-70.

  8. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77-84.

  9. Ettinger B, Pak CY, Citron JT, et al. Potassium magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069-73.

  10. Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;315:1386-9.

  11. Ettinger B, Citron JT, Livermore B, et al. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 1988;139:679-84.

  12. Drongelen JV, Kiemeney LALM, Debruyne FMJ, De la Rosette JJMCH. Impact of urometabolic evaluation on prevention of urolithiasis: a retrospective study. Urology 1998;52:384-91.

  13. Lotan Y, Pearle MS. Economics of stone management. Urol Clin North Am 2007;34:443-53.

  14. Pietrow PK, Preminger GM. Evaluation and medical management of urinary lithiasis. En Campbell-Walsh Urology. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Elsevier. 9a Ed. Philadelphia; 2007. pp.1393-1409.

  15. Pak CY, Resnick MI. Medical therapy and new approaches to management of urolithiasis. Urol Clin North Am 2000;27:243-53.

  16. Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 1980;69:19-30.

  17. Verbaeys A, Minnaert H, de Paepe M, et al. Results of urometabolic evaluation in 127 patients with renal calculous disease. Urology 1985;25:22-5.

  18. Amaro CR, Goldberg J, Amaro JL, Padovani CR. Metabolic assessment in patients with urinary litiasis. Int Braz J Urol 2005;31:29-33.

  19. Massari PU, Garay G, Holz RM. Experiencia Latinoamericana em Litíase renal. Córdoba. En: Calculose Renal. Fisiopatología, Diagnóstico, Tratamiento. Sao Paulo. Sarvier; 1995.pp.342-346.

  20. Weisinger JR, Vellorí Font E. Experiencia Latinoamericana em Litíase renal. Venezuela. En: Calculose Renal. Fisiopatología, Diagnóstico, Tratamiento. Sao Paulo. Sarvier; 1995.pp.354-359.

  21. Ossandón E, Storme O, Ledesma R, et al. Resultados del estudio metabólico en 54 pacientes con urolitiasis de alto riesgo de recurrencia. Actas Urol Esp 2009;33:429-32.

  22. Lancina JA, Rodríguez-Rivera J, Novás S, et al. Factores de riesgo metabólico en urolitiasis cálcica según el sexo y edad de los pacientes. Actas Urol Esp 2002;26:111-120.




2020     |     www.medigraphic.com